GSK Grants Long-Term Notional Share Awards to New Executive Committee Members

GlaxoSmithKline ( (GB:GSK) ) just unveiled an announcement.

GSK has granted notional share awards under its Deferred Investment Award programme to two newly appointed Executive Committee members, President of Europe Lynn Baxter and Chief Patient Officer Mondher Mahjoubi. The awards, each covering 3,020 notional ordinary shares at a reference price of £21.41, are designed to recognise outstanding 2025 performance and will vest in cash on 12 February 2029, subject to continued service.

The scheme forms part of GSK’s wider performance framework for its general employee population and is structured to align senior leaders’ incentives with long-term shareholder interests. Executive directors are excluded from this programme, underscoring a differentiated approach to remuneration across leadership tiers while reinforcing retention and stability within the expanded executive committee.

The most recent analyst rating on (GB:GSK) stock is a Buy with a £24.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

Spark’s Take on GB:GSK Stock

According to Spark, TipRanks’ AI Analyst, GB:GSK is a Neutral.

The score is driven primarily by strong profitability and improving recent fundamentals, supported by constructive 2026 guidance and pipeline momentum. Valuation is reasonable with a modest yield, while the main constraint is technical overbought risk and ongoing balance-sheet/earnings-consistency considerations.

To see Spark’s full report on GB:GSK stock, click here.

More about GlaxoSmithKline

GSK plc is a global biopharmaceutical company focused on uniting science, technology and talent to develop medicines and vaccines that help people get ahead of disease. The London-headquartered group operates across major healthcare markets, targeting a broad range of therapeutic areas with a strategy built around long-term innovation and shareholder value.

Average Trading Volume: 8,753,641

Technical Sentiment Signal: Buy

Current Market Cap: £87.35B

See more insights into GSK stock on TipRanks’ Stock Analysis page.